INNOCARE(09969.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 105.82 million, YoY increase of 488.93%
Tags：
- INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline
- INNOCARE(09969.HK): NDA of Orelabrutinib for ITP Accepted by NMPA
- InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully
